Caribou Biosciences, Inc.
CRBUFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Caribou Biosciences, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Feb 27, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| JANE STREET GROUP, LLC | 2026-03-31 | 24,975 | $47.5K | SEC filing |
| Diametric Capital, LP | 2026-03-31 | 32,793 | $62.3K | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-03-31 | 836,903 | $1.59M | SEC filing |
| Gen-Wealth Partners Inc | 2026-03-31 | 136 | $258 | SEC filing |
| PFM Health Sciences, LP | 2026-03-31 | 957,787 | $1.82M | SEC filing |
| Signature Equity Partners, LLC | 2026-03-31 | 177 | $336 | SEC filing |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 2026-03-31 | 117,500 | $223K | SEC filing |
| BANK OF MONTREAL /CAN/ | 2026-03-31 | 21,000 | $39.9K | SEC filing |
| STATE STREET CORP | 2026-03-31 | 423,263 | $804K | SEC filing |
| GREAT VALLEY ADVISOR GROUP, INC. | 2026-03-31 | 14,314 | $27.7K | SEC filing |
| Atlantic Union Bankshares Corp | 2026-03-31 | 3,200 | $6.08K | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 217,735 | $414K | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 26,713 | $50.8K | SEC filing |
| TWO SIGMA SECURITIES, LLC | 2026-03-31 | 13,052 | $24.8K | SEC filing |
| Next Capital Management LLC | 2026-03-31 | 20,000 | $38K | SEC filing |
| Vanguard Personalized Indexing Management, LLC | 2026-03-31 | 39,233 | $74.5K | SEC filing |
| Scarborough Advisors, LLC | 2026-03-31 | 8,420 | $16K | SEC filing |
| AXQ CAPITAL, LP | 2026-03-31 | 15,000 | $28.5K | SEC filing |
| AMERIPRISE FINANCIAL INC | 2026-03-31 | 29,430 | $55.9K | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 2,462 | $5K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Caribou Biosciences, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-03-14 · Haurwitz Rachel E.: Larger than 11 of the 12 other insider purchases of Common Stock on file. SEC filing
- 2022-10-06 · Fischesser Ryan: Larger than 9 of the 10 other insider sales of Common Stock on file. SEC filing
- 2022-08-25 · Kanner Steven: Larger than all 10 other insider sales of Common Stock on file. SEC filing
- 2021-10-12 · Kanner Steven: Larger than all 12 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P · Chief Technology Officer | Common Stock | S — Open market or private sale | −6,228 | 1.93 | SEC filing |
| 2026-02-24 | Albertson Tina M. · Chief Medical Officer | Common Stock | S — Open market or private sale | −1,066 | 1.96 | SEC filing |
| 2026-02-24 | Kelly Timothy P · Chief Technology Officer | Common Stock | S — Open market or private sale | −3,147 | 1.96 | SEC filing |
| 2026-02-24 | MCCLUNG BARBARA G · Chief Legal Officer | Common Stock | S — Open market or private sale | −6,938 | 1.96 | SEC filing |
| 2026-02-24 | Khan Ruhi Ahmad · Chief Business Officer | Common Stock | S — Open market or private sale | −6,938 | 1.96 | SEC filing |
| 2025-03-14 | Haurwitz Rachel E. · President and CEO | Common Stock | P — Open market or private purchase | +20,000 | 1.02 | SEC filing |
| 2025-02-21 | Kanner Steven · Chief Scientific Officer | Common Stock | S — Open market or private sale | −3,564 | 1.35 | SEC filing |
| 2025-02-21 | MCCLUNG BARBARA G · Chief Legal Officer | Common Stock | S — Open market or private sale | −3,564 | 1.35 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-02-20 | Kelly Timothy P · Chief Technology Officer | Option to purchase Common Stock | A — Grant, award, or other acquisition | +202,500 | SEC filing |
| 2026-02-20 | Albertson Tina M. · Chief Medical Officer | Common Stock | A — Grant, award, or other acquisition | +55,000 | SEC filing |
| 2026-02-20 | Haurwitz Rachel E. · President and CEO | Option to purchase Common Stock | A — Grant, award, or other acquisition | +682,500 | SEC filing |
| 2026-02-20 | JOHNSON DAVID LEE · Director | Option to purchase Common Stock | A — Grant, award, or other acquisition | +45,000 | SEC filing |
| 2026-02-20 | Albertson Tina M. · Chief Medical Officer | Option to purchase Common Stock | A — Grant, award, or other acquisition | +247,500 | SEC filing |
| 2026-02-20 | Khan Ruhi Ahmad · Chief Business Officer | Common Stock | A — Grant, award, or other acquisition | +45,000 | SEC filing |
| 2026-02-20 | Sacks Natalie · Director | Option to purchase Common Stock | A — Grant, award, or other acquisition | +45,000 | SEC filing |
| 2026-02-20 | Whiting Nancy · Director | Option to purchase Common Stock | A — Grant, award, or other acquisition | +45,000 | SEC filing |
Showing 8 of 22 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.